Form D · Biotechnology
Elixirgen, LLC
Baltimore, MD · CIK 0001547486
Offering snapshot reported Apr 23, 2012 · SEC filing
- Reported sold
- $300K Offering amount: $1M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $100K Reported outside-investor minimum
- First sale
- Apr 7, 2012 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 23, 2012 | Initial | $300,000 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-177100
Source: Form D, filed Apr 23, 2012. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Naomi Takahashi Ko | Executive |
| Minoru Shil Hong Ko | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
855 N. Wolfe Street Suite 621
Baltimore, MD, 21205
Baltimore, MD, 21205